Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy

Experimental Cell Research

Volumn 319, Issue 17, 2013, Pages 2673-2683

  Whitman, Samantha A ^a   Long, Min ^a,b   Wondrak, Georg T ^a   Zheng, Hongting ^b   Zhang, Donna D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atrophy; Metabolism; Myosin; Nrf2; Skeletal muscle

Indexed keywords

ISOPROTEIN; MYOSIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SMALL INTERFERING RNA; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GENOTYPE; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE DEVELOPMENT; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES;

EID: 84885381993     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.07.015     Document Type: Article

References (30)

1. Sacheck J.M., Ohtsuka A., McLary S.C., Goldberg A.L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1, American journal of physiology. Endocrinol. Metab. 2004, 287:E591-601.
2. Jackman R.W., Kandarian S.C. The molecular basis of skeletal muscle atrophy. Am. J. Physiol. - Cell Physiol. 2004, 287:C834-C843.
3. Aragno M., Mastrocola R., Catalano M.G., Brignardello E., Danni O., Boccuzzi G. Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes 2004, 53:1082-1088.
4. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53:401-426.
5. Burton N.C., Kensler T.W., Guilarte T.R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006, 27:1094-1100.
6. Ma Q., Battelli L., Hubbs A.F. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 2006, 168:1960-1974.
7. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J. Pineal Res. 2011, 50:124-131.
8. Zheng H., Whitman S.A., Wu W., Wondrak G.T., Wong P.K., Fang D., Zhang D.D. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60:3055-3066.
9. Cui W., Bai Y., Miao X., Luo P., Chen Q., Tan Y., Rane M.J., Miao L., Cai L. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxidative Med. Cell. Longevity 2012, 2012:821936.
10. Pergola P.E., Raskin P., Toto R.D., Meyer C.J., Huff J.W., Grossman E.B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D.G. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl. J. Med. 2011, 365:327-336.
11. C. Zoja, D. Corna, V. Nava, M. Locatelli, F. Abbate, F. Gaspari, F. Carrara, F. Sangalli, G. Remuzzi, A. Benigni, Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects, Am. J. Physiol. Renal Physiol. 2013 Mar 15;304(6):F808-19. 10.1152/ajprenal.00376.2012. Epub 2012 Nov 7.
12. Yang B., Fu J., Zheng H., Xue P., Yarborough K., Woods C.G., Hou Y., Zhang Q., Andersen M.E., Pi J. Deficiency in the nuclear factor E2-related factor 2 renders pancreatic beta-cells vulnerable to arsenic-induced cell damage. Toxicol. Appl. Pharmacol. 2012, 264:315-323.
13. Li B., Liu S., Miao L., Cai L. Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp. Diabetes Res. 2012, 2012:216512.
14. Wang X., Wu H., Chen H., Liu R., Liu J., Zhang T., Yu W., Hai C. Does insulin bolster antioxidant defenses via the extracellular signal-regulated kinases-protein kinase B-nuclear factor erythroid 2 p45-related factor 2 pathway?. Antioxid. Redox Signaling 2012, 16:1061-1070.
15. Yu Z.W., Li D., Ling W.H., Jin T.R. Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: a novel opportunity for diabetes treatment?. World J. Diabetes 2012, 3:19-28.
16. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 1994, 91:9926-9930.
17. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
18. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
19. Lamprecht M.R., Sabatini D.M., Carpenter A.E. CellProfiler: free, versatile software for automated biological image analysis. Bio. Tech. 2007, 42:71-75.
20. Wada M., Hamalainen N., Pette D. Isomyosin patterns of single type IIB, IID and IIA fibres from rabbit skeletal muscle. J. Muscle Res. Cell Motil. 1995, 16:237-242.
21. Aleksunes L.M., Reisman S.A., Yeager R.L., Goedken M.J., Klaassen C.D. Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. J. Pharmacol. Exp. Ther. 2010, 333:140-151.
22. Diffee G.M., Kalfas K., Al-Majid S., McCarthy D.O. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am. J. Physiol. - Cell Physiol. 2002, 283:C1376-C1382.
23. Gosker H.R., van Mameren H., van Dijk P.J., Engelen M.P., van der Vusse G.J., Wouters E.F., Schols A.M. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur. Respir. J.: Official J. Eur. Soc. Clin. Respir. Physiol. 2002, 19:617-625.
24. Piao Y.J., Seo Y.H., Hong F., Kim J.H., Kim Y.J., Kang M.H., Kim B.S., Jo S.A., Jo I., Jue D.M., Kang I., Ha J., Kim S.S. Nox 2 stimulates muscle differentiation via NF-kappaB/iNOS pathway. Free Radical Biol. Med. 2005, 38:989-1001.
25. Barbieri E., Sestili P. Reactive oxygen species in skeletal muscle signaling. J. Signal Transduct. 2012, 2012:982794.
26. Choi C.S., Befroy D.E., Codella R., Kim S., Reznick R.M., Hwang Y.J., Liu Z.X., Lee H.Y., Distefano A., Samuel V.T., Zhang D., Cline G.W., Handschin C., Lin J., Petersen K.F., Spiegelman B.M., Shulman G.I. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc. Natl. Acad. Sci. USA 2008, 105:19926-19931.
27. Lin J., Wu H., Tarr P.T., Zhang C.Y., Wu Z., Boss O., Michael L.F., Puigserver P., Isotani E., Olson E.N., Lowell B.B., Bassel-Duby R., Spiegelman B.M. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
28. Chang J.H., Lin K.H., Shih C.H., Chang Y.J., Chi H.C., Chen S.L. Myogenic Basic Helix-Loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-γ coactivator-1α. Endocrinology 2006, 147:3093-3106.
29. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., Goldblatt C.S., Meyer C.J., Li X., Cai L., Cui T. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
30. Krause M.P., Riddell M.C., Gordon C.S., Imam S.A., Cafarelli E., Hawke T.J. Diabetic myopathy differs between Ins2Akita+/'àí and streptozotocin-induced Type 1 diabetic models. J. Appl. Physiol. 2009, 106:1650-1659.